C1 Esterase Inhibitor - Pipeline Insight 2018 - ResearchAndMarkets.com
The "C1 Esterase Inhibitor - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
C1 Esterase Inhibitor - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across C1 Esterase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for C1 Esterase Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active C1 Esterase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. C1 Esterase Inhibitor - Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. C1 Esterase Inhibitor Pipeline Products in Clinical Stages
6. C1 Esterase Inhibitor Pipeline Products in Non-clinical Stages
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
- CSL Behring
- True North Therapeutics
- Pharming Group NV
- Shire ViroPharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/26nhzv/c1_esterase?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181221005382/en/